NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Tuesday that its fourth quarter revenues declined 7 percent year over year on slower influenza and respiratory disease business.
NEW YORK (GenomeWeb News) – Quidel announced that for full-year 2013 it anticipates reporting $175 million in revenues.
That would represent a 12 percent bump up from $155.7 million recorded in 2012 and would beat the average analyst estimate of $174.0 million.
NEW YORK (GenomeWeb News) – Quidel said after the close of the market on Monday that the US Food and Drug Administration has cleared the company's AmpliVue Group B Strep Assay, the second assay to receive FDA clearance to run on the AmpliVue handheld molecular testing platform.
The US Food and Drug Administration has granted 510(k) clearance to Quidel's Molecular Influenza A+B and RSV+hMPV assays for use on Life Technologies' QuantStudio Dx real-time PCR instrument, the companies said this week.